Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Cash & Equivalents data on record, last reported at $226.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 192.86% year-over-year to $226.7 million; the TTM value through Dec 2025 reached $226.7 million, up 192.86%, while the annual FY2025 figure was $226.7 million, 192.86% up from the prior year.
  • Cash & Equivalents reached $226.7 million in Q4 2025 per AMLX's latest filing, up from $225.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $247.8 million in Q2 2023 and bottomed at $50.2 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $119.4 million, with a median of $107.7 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 267.38% in 2023, then crashed 69.73% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $50.2 million in 2021, then increased by 24.58% to $62.5 million in 2022, then surged by 172.21% to $170.2 million in 2023, then tumbled by 54.53% to $77.4 million in 2024, then skyrocketed by 192.86% to $226.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $226.7 million in Q4 2025, $225.2 million in Q3 2025, and $58.1 million in Q2 2025.